The purpose of this study is to study the relationships between obesity, hormones and menopausal status, and breast cancer. The researchers would like to study whether a type of nutritional intervention, called a time-restricted diet or tRD, is easy to maintain using a smartphone application; the researchers also want to study the effect that a tRD has on weight control, hormones, and breast tissue. A tRD is a type of diet that requires people to restrict their daily eating to a specific time frame each day. The researchers think that this might be an effective and manageable way to control weight.
PRIMARY OBJECTIVES: I. Feasibility of fostering adherence to self-monitoring of dietary intake using a smartphone application (app). II. Feasibility of the goal of following a time-restricted diet. SECONDARY OBJECTIVES: I. Identify potential molecular biomarkers and/or signatures to explore its efficacy for the normalization of metabolism. II. Assess the systemic endocrine effects of a time restricted diet (tRD) intervention in overweight and obese pre and postmenopausal women. III. Assess weight change following a tRD intervention. IV. Evaluate the effects of a tRD intervention, and identify a specific and reproducible genomic signature, in breast samples obtained by random fine needle aspiration in the tRD study population. V. Assess the volume of parenchymal enhancement on magnetic resonance imaging (MRI). OUTLINE: Participants follow a time restricted diet, which restricts daily eating to an 8 hour time window between 12:00-8:00 pm. Participants are allowed to consume non-caloric beverages (water, black tea, black coffee, diet soda, etc.) during the fasting hours and required to record daily food consumption in the smartphone app for 6 months. Participants are also coached by telephone over approximately 10-15 minutes weekly for 1 month and then biweekly for 5 months. After completion, participants are followed up for 3 months.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
PREVENTION
Masking
NONE
Enrollment
45
Follow tRD
Receive coaching calls
Correlative studies
Northwestern University
Chicago, Illinois, United States
Adherence to self-monitoring
Assessed by demonstrating that at least 65% of participants record dietary intake on at least 80% of study intervention days. Adherence will be assessed via a one-sample chi-squared test for proportions.
Time frame: Up to 3 months after completion of study
Attaining the goal of dietary time restriction
Assessed by demonstrating that at least 65% of participants recorded appropriate time restriction on at least 80% of study days.
Time frame: Up to 3 months after completion of study
Changes in steroid hormones (estradiol, progesterone, testosterone) levels
Blood samples will be taken and representative values (mean, standard deviation, median, and range) of hormones and adipokine measurements will be used to calculate changes following intervention, which will then be used for univariate analysis using menopausal status and change in BMI as the main predictors of interest. These analyses are exploratory and descriptive of the systemic endocrine/adipokine environment; they will be related to gene expression changes. Correlations between changes in BMI and changes in biomarker levels will be assessed via the Spearman correlation.
Time frame: Baseline to up to 3 months after completion of study
Changes in gonadotropins (FSH) levels
Blood samples will be taken and representative values (mean, standard deviation, median, and range) of hormones and adipokine measurements will be used to calculate changes following intervention, which will then be used for univariate analysis using menopausal status and change in BMI as the main predictors of interest. These analyses are exploratory and descriptive of the systemic endocrine/adipokine environment; they will be related to gene expression changes. Correlations between changes in BMI and changes in biomarker levels will be assessed via the Spearman correlation.
Time frame: Baseline to up to 3 months after completion of study
Changes in insulin axis (insulin, insulin-like growth factor 1, IGF binding protein 3, homeostatic model assessment, homocystein) levels
Blood samples will be taken and representative values (mean, standard deviation, median, and range) of hormones and adipokine measurements will be used to calculate changes following intervention, which will then be used for univariate analysis using menopausal status and change in BMI as the main predictors of interest. These analyses are exploratory and descriptive of the systemic endocrine/adipokine environment; they will be related to gene expression changes. Correlations between changes in BMI and changes in biomarker levels will be assessed via the Spearman correlation.
Time frame: Baseline to up to 3 months after completion of study
Changes in adipokines (leptin, adiponectin, low molecular weight adiponectin) levels
Blood samples will be taken and representative values (mean, standard deviation, median, and range) of hormones and adipokine measurements will be used to calculate changes following intervention, which will then be used for univariate analysis using menopausal status and change in BMI as the main predictors of interest. These analyses are exploratory and descriptive of the systemic endocrine/adipokine environment; they will be related to gene expression changes. Correlations between changes in BMI and changes in biomarker levels will be assessed via the Spearman correlation.
Time frame: Baseline to up to 3 months after completion of study
Changes in inflammatory axis (interleukin-6, tumor necrosis factor alpha) levels
Blood samples will be taken and representative values (mean, standard deviation, median, and range) of hormones and adipokine measurements will be used to calculate changes following intervention, which will then be used for univariate analysis using menopausal status and change in BMI as the main predictors of interest. These analyses are exploratory and descriptive of the systemic endocrine/adipokine environment; they will be related to gene expression changes. Correlations between changes in BMI and changes in biomarker levels will be assessed via the Spearman correlation.
Time frame: Baseline to up to 3 months after completion of study
Changes in weight
The pre- and post-intervention measures and within-individual changes in weight be summarized and examined for Normality and outliers; required transformations to achieve Normality will be performed.
Time frame: Baseline to up to 3 months after completion of study
Changes in BMI
The pre- and post-intervention measures and within-individual changes in BMI will be summarized and examined for Normality and outliers; required transformations to achieve Normality will be performed. Pre-post comparisons of BMI will be performed using paired Wilcoxon signed-rank tests to evaluate changes over time, designating P \< 0.05 as significant.
Time frame: Baseline to up to 3 months after completion of study
Changes in breast epithelial gene expression
Gene expression for all 58 genes on the Taqman low density gene expression assays will be summarized to confirm normality and discern outliers. Each gene will then be analyzed using a linear model with the main effect of menopausal status and change in BMI, baseline gene expression and change in expression will be correlated to baseline steroid hormones and adipokines, and their change. If severe departure from normality is observed, these linear models will be applied to ranks of the data.
Time frame: Baseline to up to 3 months after completion of study
Changes in parenchymal volume assessed by MRI
The volume of parenchymal enhancement on MRI will be assessed pre and post intervention in women who consent to this optional component.
Time frame: Baseline to up to 3 months after completion of study
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.